The mouse TSH receptor ectodomain (mTSHR-ecd) was amplified from murine thyroid complementary DNA and ligated into the pAcGP67B insect cell vector, and the nucleotide sequence was confirmed. Employing a baculovirus-insect cell system, the mTSHR-ecd (amino acids 22-415) was expressed as a fusion protein with the gp67 insect cell signal sequence at the NH 2 -terminus and a C-terminal six-histidine tag. Protein expression was assessed by Western blot using a murine monoclonal antibody (recognizing amino acids 22-35) and a rabbit antipeptide antibody (recognizing amino acids 397-415). These antibodies detected two principal species of mTSHR-ecd, one glycosylated (66 kDa) and one nonglycosylated (52 kDa), in cell lysates of infected insect cells. More than 10% of these species were present in a water-soluble (cytosolic) fraction. This fraction was then used to purify, under native conditions, 100-g amounts of mTSHR-ecd using nickel-nitrilo-triacetic (Ni-NTA) resin chromatography. The purified cytosolic mTSHR-ecd migrated as a homogeneous 66-kDa band visible on Coomassie blue-stained gels and was confirmed by Western blotting. We also purified the mTSHR-ecd from total cell lysates under denaturing conditions, followed by "in vitro" refolding on the Ni-NTA column. Under these conditions, milligram amounts of soluble mT-SHR-ecd were obtained. This material consisted primarily of the 66-kDa glycosylated form, but in addition contained four or five lower molecular mass, partially glycosylated intermediates and the 52-kDa nonglycosylated form. Deglycosylation with either endoglycosidase F or H, reduced all mTSHR-ecd glycosylated species to a 52-kDa nonglycosylated form. Both the cytosolic and refolded mTSHR-ecd preparations inhibited the binding of [
T SH INFLUENCES thyroid epithelial cell function via a
prototypical G protein-linked receptor with a large extracellular domain (TSHR-ecd) (1) . The TSHR is the major autoantigen of Graves' disease. This is a uniquely human disease associated with hyperthyroidism secondary to TSHR stimulation by TSHR autoantibodies (hTSHR-Abs), which act as TSH agonists (2) . Since the early discovery of TSHRAbs, the mouse has served as a potent bioassay of human thyroid-stimulating antibody activity (3), indicating that mouse TSHR (mTSHR) is immunologically similar to that in the human. However, only a minority of hTSHR-Abs act as TSH agonists at the mTSHR (4), and binding/activity studies have shown that many hTSHR-Abs bind to the mTSHR without activating the receptor (5, 6) . The structural mechanism for this dissociation is unknown. Sequencing of the mTSHR has indicated a number of potentially important differences from the hTSHR sequence (7) , and this may explain the species specificity of hTSHR-Abs.
In addition to serving as a bioassay for hTSHR-Abs, the mouse exhibits thyroid antigen-induced experimental autoimmune thyroiditis. This model has become one of the most common tools for understanding the mechanism of autoimmune dysfunction (8) . In the past, both thyroglobulin and thyroid peroxidase have been shown to initiate experimental autoimmune thyroiditis, using either human and/or mouse antigens (9 -11) . Recently, attempts to initiate autoimmune thyroid disease with hTSHR-ecd antigen have been largely unsuccessful. While one group has claimed success (12), we and others have failed to initiate thyroiditis, although marked immune responses to the immunizing antigen have been obtained (13) (14) (15) . Such data again suggested that the mouse TSHR may be immunologically distinct from the human TSHR.
To address these questions it is necessary to characterize the mTSHR and evaluate its immunological effects. We have succeeded in producing large quantities of eukaryotic mouse TSHR ectodomain and have characterized highly purified preparations for binding of TSH ligand and TSHR-Abs.
Materials and Methods

Characterization of murine TSHR messenger RNA (mRNA)
Total RNA from human thyroid and mouse tissues was extracted using Tri-Reagent (Molecular Research Center, Cincinnati, OH). Mouse thyroid total RNA was obtained from two groups of mice: group A (32 normal CBA/J mice) and group B (20 CBA/J mice; treated with 0.05% methimazole and a low iodine diet for 4 weeks). Polyadenylated [poly (A) ϩ ] RNA was prepared using a poly(A) ϩ Tract magnetic bead mRNA isolation system (Promega, Madison, WI). For Northern blot hybridization, 4.5 g poly(A) ϩ RNA were loaded onto 1% agarose gels, electrophoresed, and transferred onto supported nitrocellulose membranes. mTSHR mRNAs were detected using a 32 P-labeled complementary DNA (cDNA) probe (nucleotides 106 -549) generated by reverse transcription-PCR (RT-PCR) and labeled by random hexamer priming (16) .
Amplification and sequencing of mTSHR-ecd
The mTSHR-ecd (bp 61-1245) was amplified by RT-PCR using CBA/J murine thyroid cDNA as the template, Vent DNA polymerase (New England Biolabs, Beverly, MA), and the following mTSHR-ecd-specific primers: forward (5Ј-GATCGGATCCGGCAAAGAGTGTGCGTCTCC) and reverse (5Ј-GATCGGTACC GAATTCTTATCAGTGATGGTGAT-GGTGATGTCCACCTCCCCTGTA GCCCATGATATCTTCAC). These primers included the underlined BamHI and EcoRI restriction sites. The reverse primer comprised the mTSHR-ecd-specific complementary sequence, followed by a 9-bp spacer sequence (double underlined) coding for three glycine residues, an 18-bp sequence (in boldface) coding for six histidines (6Hi), and a synthetic stop codon (in italics). The 6Hi at the C-terminus allowed further purification of the mTSHR-ecd-6Hi using nickel-nitrilo-triacetic (Ni-NTA) resin chromatography. After amplification, the murine thyroid DNA was digested with BamHI and EcoRI, electrophoresed on 1% agarose gels, purified from excised gel slices using glassmilk (GeneClean kit, BIO 101, La Jolla, CA), and ligated into BamHI/EcoRI-digested eukaryotic pAcGP67B expression vector (PharMingen, San Diego, CA) to generate the pAcGP67B-mTSHR-ecd plasmid. After restriction analysis, the mTSHR-ecd was sequenced using the dideoxynucleotide termination method (Sequenase kit, U.S. Biochemical Corp., Cleveland, OH).
Expression of mTSHR-ecd in Hi-5 insect cells
mTSHR-ecd cDNA was inserted into the BamHI cloning site of the pAcGP67B vector downstream to the polyhedrin promoter and gp67 signal peptide (17) . Recombinant pAcGP67B/mTSHR-ecd plasmid was cotransfected with Baculo-Gold DNA into sf9 insect cells as previously described (18) . The resulting recombinant virus was then used to infect Hi-5 silkworm cells (19) . Expression of mTSHR-ecd protein was assessed by subjecting unpurified total cell lysates, particulate-insoluble fractions, and cytosolic (water-soluble) fractions obtained after sonication to SDS-PAGE followed by Coomassie blue staining (20 g total protein/ lane) and Western blot analysis (5-10 g total protein/lane), as previously described (20, 21) . Blots were developed using either murine monoclonal antibody (mAb A10, supplied by Dr. J. P. Banga, University of London), recognizing hTSHR residues 22-35 (21) , or rabbit antiserum (R 397) generated against an extreme C-terminus hTSHR peptide (residues 397-415) (22) , both at a 1:10,000 dilution. Bound antibodies were detected using enhanced chemiluminescence (ECL kit, Amersham, Aylesbury, UK).
Purification of the mTSHR-ecd
Using Ni-NTA-resin chromatography (Quiagen, Chatsworth, CA), the mTSHR-ecd was purified either from total cell lysates of infected insect cells (under denaturing conditions followed by on-column refolding) or from cytosolic fractions (under native conditions). For purification under denaturing conditions followed by refolding, insect cells harvested 65 h postinfection were solubilized in 6 m guanidine-HCl followed by centrifugation (12,000 rpm for 30 min at 15 C). For analytical purification, 8.5 mg total supernatant protein were mixed with 200 l 50% Ni-NTA resin. For larger scale purification, 20 -50 mg total protein lysate were mixed with 0.5-1 ml 50% Ni-NTA resin. After batch binding for 1 h at room temperature, the slurry was loaded onto low pressure chromatography columns (Bio-Rad, Richmond, CA) and allowed to settle, and the resin was sequentially washed with 10 vol 6 m guanidineHCl (pH 8.0), 10 vol 8 m urea (pH ϭ 8.0), and 40 vol 8 m urea (pH 6.5). The mTSHR-ecd captured by the Ni-NTA resin was further subjected to refolding in situ, by applying two consecutive linear gradients of refolding buffers (50 -75 ml each), over 10 -12 h at 4 C: gradient 1 consisted of buffer A [8 m urea, 10 mm Tris-HCl (pH 7.4), 0.5 m NaCl, 20% glycerol, and 0.1% Triton X-100], and buffer B was similar to buffer A, but contained 1 m urea. Gradient 2, started with buffer B and ended with buffer C [10 mm Tris-HCl (pH 7.4), 0.15 m NaCl, 0.1 m potassium acetate, and 0.1% Triton X-100]. The refolded mTSHR-ecd was then eluted with 10 bed volumes of 350 mm imidazole in refolding buffer C. Samples from the input, flow-through, sequential washes, and eluted mTSHR-ecd fractions were precipitated with trichloroacetic acid, dissolved in SDS-PAGE sample buffer containing 2% ␤-mercaptoethanol (␤ME), and fractionated by SDS-PAGE. Purification was evaluated initially by Coomassie blue staining (5-10 g protein/lane) and immunoblotting with the murine mAb A10 and R 397 antiserum (1-4 g protein/lane). The purified mTSHR-ecd fractions were pooled; dialyzed extensively against 10 mm Tris (pH 7.4), 0.05 m NaCl, and 0.1% Triton X; and concentrated with polyethylene glycol (M r , 20,000) to 0.25-0.5 mg/ml.
For purification of soluble mTSHR-ecd under native conditions, insect cell pellets were resuspended in sonication buffer [50 mm sodium phosphate (pH 7.4), 0.3 m NaCl, and protease inhibitor cocktail (PharMingen, San Diego, CA; catalog no. 21426Z)], and after two freeze-thaw cycles, the pellet was extracted on ice with three sonication cycles (1 min each) at 15-min intervals. Subsequently, the lysate was centrifuged at 50,000 ϫ g for 40 min, and the soluble (cytosolic) fraction was filtered through a 0.2-m filter. Filtrate (6 -10 mg) was mixed with 250 -500 l Ni-NTA resin in a binding buffer containing 0.5 m NaCl, 10 mm ␤ME, 20% glycerol, and 60 mm imidazole, followed by batch binding for 2 h at 4 C. After casting the column, the resin was extensively washed with binding buffer without ␤ME. Bound cytosolic mTSHR-ecd was then eluted with 300 mm imidazole. Purity assessment and dialysis of pooled fractions were performed as described above.
Deglycosylation of purified mTSHR-ecd
Both refolded and cytosolic mTSHR-ecd were subjected to deglycosylation with endoglycosidase F (Endo F) or endoglycosidase H (Endo H; Boehringer Mannheim, Indianapolis, IN). mTSHR-ecd samples were reduced by boiling for 3 min in the presence of 0.2% SDS, 1% ␤ME for Endo F and 0.05% SDS-2% ␤ME for Endo H, and aliquots (5 g protein) were diluted into 10 vol Endo F buffer [20 mm potassium phosphate (pH 7.5), 10 mm EDTA, and 1% Nonidet P-40]) or Endo H buffer [50 mm sodium phosphate (pH 5.5) and 0.5% Nonidet P-40]. After enzyme addition the samples were incubated for 16 h at 37 C. Proteins were precipitated with 10% trichloroacetic acid, rinsed with acetone, and dissolved in SDS-PAGE sample buffer containing 2% ␤ME. The samples were subjected to SDS-PAGE (1 g/lane) followed by immunoblotting as described above.
Binding of TSH to purified mTSHR-ecd
The ability of the mTSHR-ecd to bind TSH was tested indirectly using a competition assay. In the first step, increasing amounts of affinitypurified mTSHR-ecd protein (competitor) and [
125 I]TSH (8,000 cpm; gift from Kronus, San Clemente, CA) were combined in 300 l binding buffer (NaCl-free Hanks' Balanced Salt Solution and 280 mm sucrose) for 1 h at 23 C. Secondly, this mixture was added to JP-09 Chinese hamster ovary (CHO) cells stably expressing the wild-type human TSHR (23) (gift from Dr. G. Vassart, Free University of Brussels, Brussels, Belgium), and incubation was continued for 1.5 h at 37 C, as previously described (24) . To explore the influence of folding of the mTSHR-ecd on TSH binding, in separate experiments the refolded mTSHR-ecd was reduced, unfolded by incubation with 10 mm dithiothreitol followed by alkylation of the sulfhydryl groups of cysteine with 40 mm iodoacetamide, as described previously (25) , and incubated as described above. After incubation, the cells were washed three times with ice-cold binding buffer dissolved in 0.5 ml 1 n NaOH, and the bound radioactivity was counted. Solubilized porcine thyroid membranes enriched for TSHR (gift from Kronus) served as a positive receptor control and was used at total protein concentrations of 1.2-120 g (estimated to contain 0.06 -6 ng pTSHR). Wild-type baculovirus-infected insect cell lysate, used at similar protein concentrations as the mTSHR-ecd, served as the negative control. Competition by unlabeled bovine TSH (bTSH; Thytropar, Armour, Kankakee, IL), used at 10 Ϫ6 -10 Ϫ12 m, validated the assay. To confirm binding of ligand to the recombinant receptor and not binding of receptor to CHO cells, the refolded mTSHR-ecd was first preincubated with the JP-09 cells, and [
125 I]TSH was added after washing the cells. Throughout, bovine TSH was assumed to have a specific activity of 30 IU/mg.
Binding of hTSHR-Ab to recombinant mTSHR-ecd
Enzyme-linked immunosorbent assays were performed as previously described (15) . Briefly, 96-well microtitration plates (Immulon 2, Dynatech Laboratories, Chantilly, VA) were coated with 100 l/well purified refolded mTSHR-ecd (1 g/ml) or partially purified insect cell-expressed human TSHR-ecd (18) , refolded by gradual dilution of denaturing agents and dialysis as described previously (26), and used at 10 g/ml. Negative controls were wild-type baculovirus-infected insect cell lysate and BSA (used at 1-10 g/ml). Samples were diluted in carbonate bicarbonate buffer (pH 9.6). After coating overnight at 4 C, wells were washed, blocked, and incubated with an internationally validated hTSHR-Ab-containing serum [MRC long acting thyroid stimulator activity (LATS) Research Standard B, National Institute for Biological Standards and Control, London, UK] reconstituted to yield an activity of 7.5 mU/ml, corresponding to a 1:50 serum dilution. Sera from 14 additional patients with hyperthyroid Graves' disease, containing high levels of hTSHR-Ab as defined by porcine RRA (27) , and 6 normal sera (all at 1:50 dilutions) were also tested individually for binding to the purified refolded mTSHR-ecd and control antigens. In a separate experiment, the hTSHR-Ab positive LATS standard serum was also reacted in 2-fold serial dilutions, against refolded and unfolded mTSHRecd. Three well characterized murine monoclonal antibodies to the hTSHR-ecd (mAb A10, recognizing amino acids 22-35; mAb A9 recognizing amino acids 147-229; and mAb A7, recognizing amino acids 402-415) (21) were used as positive controls at a 1:50,000 dilution. Detection was accomplished using alkaline phosphatase-labeled antihuman IgG (A-5403, Sigma Chemical Co., St. Louis, MO) and antimouse IgG (A-0532, Sigma Life Sciences), and absorption was measured after 1 h at 405 nm.
Results
Characterization of murine thyroidal mRNA
As shown in Fig. 1A , the mTSHR-ecd cDNA probe hybridized to four mTSHR mRNAs with estimated lengths of 4.3, 3.5, 2.9, and 1 kilobases (kb; lane 2) present in the thyroid mRNA of euthyroid CBA/J mice (group A). In this experiment, the 2.9-kb transcript was the most abundant. The mouse cDNA probe also hybridized to three hTSHR mRNAs in a human thyroid sample (lane 1); these migrated at 4.3, 1.7, and 1.3 kb and were previously characterized by our laboratory (28) . In this sample, the 4.3-kb transcript was the most abundant. A second Northern blot of murine thyroid mRNA, extracted from CBA/J mice treated with methimazole and a low iodine diet to induce TSH stimulation (group B), demonstrated a similar set of four mTSHR transcripts, also with the 2.9-kb transcript the most abundant (Fig. 1B, lane 1) . No mTSHR-ecd transcripts were detected in mRNAs extracted from mouse brain, muscle, or liver (Fig. 1B, lanes 2-4) .
Amplification and sequencing of mTSHR-ecd
The RT-PCR product of CBA/J mTSHR-ecd cDNA yielded a unique, appropriately sized, 1200-bp band in 1% agarose gels, detected by ethidium bromide staining. After purification, the DNA was ligated into the pAcGP67 B vector, and the product was used to transform Escherichia coli. Plasmid insert from three clones were sequenced. The translated sequence differed by only six amino acids from the published mTSHR sequence (7). The differences (Table 1 ) had a high substitution probability among proteins of common ancestry, as evaluated using a matrix of relative substitution frequencies (29) . This frequency of substitution could have been due to simple polymorphisms and/or mouse strain (BALB/c vs. CBA/J) differences. Compared to the sequence of the hTSHR-ecd, 62 amino acid differences were noted (Table 1) .
Insect cell expression of mTSHR-ecd protein
As detected with mAb A10 ( Fig. 2A ) and R 397 (Fig. 2B) , infection of Hi-5 insect cells with recombinant baculoviruses containing mTSHR-ecd cDNA induced high level expression of two major mTSHR-ecd proteins with apparent molecular masses of 66 kDa (glycosylated) and 52 kDa (corresponding to the predicted molecular size of unglycosylated mTSHRecd). Both species were detected in the total cell lysate (Fig.  2, A and B, lane 1) , the particulate-insoluble fraction (Fig. 2 , A and B, lane 2), and the cytosolic (water-soluble) fraction (Fig. 2, A and B, lane 3) . As evaluated by Coomassie blue staining, these proteins were enriched in the insoluble fraction (not shown). Very small amounts were detectable by Western blot in the culture medium despite the presence of the baculovirus gp67 signal peptide on the nascent mTSHRecd proteins (not shown). Nevertheless, significant amounts (Ͼ10%) of the mTSHR-ecd species were present in the cytosolic fraction. This enabled us to purify natively folded mTSHR-ecd present in this fraction and compare it with mTSHR-ecd purified from total cell lysates, followed by in vitro refolding. Neither of the detected species was present in similar cell fractions obtained from wild-type baculovirusinfected insect cells (not shown).
Purification of eukaryotic mTSHR-ecd
Purification of mTSHR-ecd under denaturing conditions followed by refolding. As shown by Coomassie blue staining and Western blotting (Fig. 3, A and C) , the mTSHR-ecd was purified to homogeneity after Ni-NTA column elution, being most enriched in eluted fractions 3 and 4 (lanes 5 and 6). The purified mTSHR-ecd again comprised two major species, migrating at 66 and 52 kDa, and lower amounts of partially glycosylated forms, migrating between 52-66 kDa (Fig. 3B) . Each of the mTSHR-ecd species identified on Coomassie blue staining was recognized by mAb A10 in Western blots. The facts that mAb A10 is recognizing an epitope at the extreme NH2-terminus (amino acids [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , and the C-terminus was immobilized by the Ni-NTA resin before elution confirm the identity and integrity of all mTSHR-ecd species purified. The total cell lysate (starting material), flow-through, and last high stringency wash are shown in lanes 1-3 of Fig. 3 , A and C.
Using this approach, milligram amounts of refolded soluble mTSHR-ecd could be purified. The eluted fractions represented 1-3% of the total protein input.
Purification of the cytosolic mTSHR-ecd.
A similar analysis of soluble mTSHR-ecd, purified using native conditions, is shown in Fig. 4 . As shown by Coomassie blue staining (Fig.  4A) , the purified cytosolic mTSHR-ecd migrated as a unique broad band around 66 kDa and was enriched in the eluted fractions 3 and 4 (lanes 2 and 3). A control represented by an enriched unpurified insoluble fraction from insect cells expressing the mTSHR-ecd is shown in lane 4. This fraction contained the 66-kDa mTSHR-ecd as a major protein and also lower mol wt contaminant proteins, absent in lanes 2 and 3 containing the purified mTSHR-ecd. Immunoblotting with mAb A10 confirmed the Coomassie blue data by identifying the purified mTSHR-ecd fractions (lanes 4 -7) . The unpurified cytosolic fraction (input), flow-through, and last wash 
The CBA/J mTSHR-ecd sequence is shown, and the six amino acid differences compared to the published BALB/c mTSHR sequence are in italics (above). Under the mTSHR-ecd sequence, we show amino acids that are different in the human TSHR (boldfaced). Sixty-two amino acid differences (85% similarity) were found between the extracellular regions of the murine and human TSHR. are shown in lanes 1-3. Under native conditions, the 66-kDa major glycoform was predominant in the purified fractions of cytosolic mTSHR-ecd compared with the purification under denaturing/refolding conditions, where a spectrum of lower mol wt glycosylated intermediates and the 52-kDa nonglycosylated form were also purified (Fig. 4B, lane 8 ). Using this method, 100-g amounts of cytosolic mTSHR-ecd could be purified, representing 0.2-0.5% of the total protein input.
Deglycosylation of purified mTSHR-ecd
When refolded mTSHR-ecd was deglycosylated, using Endo F, which cleaves high mannose and complex carbohydrate side-chains, the 66-kDa species was converted to 52 kDa, confirming the glycosylated state of the 66-kDa form (Fig. 5A, lanes 1 and 2) . The smaller amounts of partially glycosylated intermediates (not as evident here) were also reduced. Similar results were obtained after digestion with Endo H, which is known to cleave only high mannose sugars (Fig. 5A, lanes 3 and 4) . Figure 5B shows that these enzymes had the same effect on the 66-kDa glycosylated species purified from the cytosol using native conditions. These deglycosylation patterns demonstrate that no significant differences could be found in the glycosylation status of the two mTSHR-ecd preparations, and that most of the carbohydrate side-chains were of the high mannose type. This finding is not unexpected, as it is known that insect cells are able to add high mannose oligosaccharides to N-acetylglucosamine residues linked to asparagine and to partially trim these structures to shorter oligosaccharides, but are generally not able to add complex sugars such as galactose and sialic acid to the trimmed sugar backbone (19) .
Binding of TSH to purified mTSHR-ecd
JP-09 CHO cells stably expressing functional hTSHR bound 2300 -3500 cpm (35-42%) of the total [125 I]TSH. Unlabeled bTSH inhibited this binding in a dose-dependent manner, with 50% inhibition achieved with concentrations of 6 -8 ϫ 10 Ϫ9 m (ϳ10 3 mIU/L; Fig. 6B, inset) . Solubilized porcine TSHR, known to bind TSH with high affinity (28), also inhibited the binding of [ 125 I]TSH to the hTSHR expressed in CHO cells in a dose-dependent manner (Fig. 6A) , confirming the validity of the assay. Based on quantitative data derived from Western blot analyses, nanogram amounts of the porcine TSHR were effective at inhibiting [ 125 I]TSH binding, achieving 50% inhibition at a concentration of ϳ5 ϫ 10 Ϫ11 m. Both the purified cytosolic and refolded mTSHR-ecd similarly inhibited labeled TSH binding in a dose-dependent manner. The inhibition induced by the two preparations had almost identical affinities, confirming the functional activity of both preparations (Fig. 6A) . Although concentrations of 2 ϫ 10 Ϫ7 m for the cytosolic and 3.3 ϫ 10 Ϫ7 m for the refolded receptor produced almost complete inhibition, 50% inhibition was achieved by concentrations of 4 -5 ϫ 10 Ϫ8 m (Fig.  6A) . Compared to the inhibitory effect of unlabeled bTSH, the affinity of the purified mTSHR-ecd was lower by about 1 log. The wild-type baculovirus-infected insect cell protein lysate (subjected to similar mock procedures as the purified mTSHR-ecd) did not compete for [
125 I]TSH binding to the hTSHR-CHO cells (Fig. 6A) (Fig. 6A) . The unfolded mTSHR-ecd preparation was intact and migrated at the correct molecular mass, as evaluated by immunoblotting with mAb A10 and mAb A7 (not shown). These data demonstrated the critical importance of the folding state of the mTSHR-ecd for TSH binding.
Binding of hTSHR-Ab to purified mTSHR-ecd
The direct binding of different hTSHR-Abs to soluble refolded mTSHR-ecd was assessed using enzyme-linked immunosorbent assays. This recombinant receptor was highly 1 and 3) . Deglycosylation with Endo F or Endo H reduced the 66-kDa species to a 52-kDa nonglycosylated form (lanes 2 and 4) . Western blot after reducing SDS-PAGE of 1 g protein/lane, developed with mAb A10 (1:10,000 dilution) . B, Deglycosylation of the cytosolic mTSHRecd. The cytosolic receptors not subjected to deglycosylation with Endo F or Endo H contain the 66-kDa glycosylated form (lanes 1 and 3). Treatment with Endo F or Endo H reduced this glycoprotein to a 52-kDa nonglycosylated species (lanes 2 and 4). The blot was developed with mAb A10 (1:10,000 dilution).
immunoreactive with murine monoclonal antibodies, recognizing three different TSHR epitopes: mAb A9 (amino acids 147-229; Figs. 7A and 8), mAb A7 (amino acids 402-415; not shown), and mAb A10 (amino acids 22-35; Fig. 7B ). The functional relevance of the refolded mTSHR-ecd immunoreactivity was further demonstrated by the marked degree of binding of a standard Graves' TSHR-Ab-positive serum (expressed in MRC LATS Standard B units) and tested in 1:50 and 1:100 serum equivalent dilutions (Fig. 7A) . This standard serum also recognized an hTSHR-ecd preparation, but did not react with wild-type baculovirus-infected insect cell control protein lysate or BSA (Fig. 7A) . The recognition of recombinant mTSHR-ecd by hTSHR-Ab was confirmed by the examination of 14 additional serum samples from patients with hyperthyroid Graves' disease with high titers of hT-SHR-Ab (as determined by competition with labeled TSH for binding to porcine TSHR). The purified refolded mTSHR-ecd interacted with 4 of the 14 Graves' sera (28%), but did not react with any of 6 normal control sera negative for hT-SHR-Ab (Fig. 8) . None of the Graves' or normal sera reacted with control antigens (Fig. 8) .
Influence of folding on TSHR-Ab recognition of mTSHR-ecd
To evaluate the influence of folding on the recognition of mTSHR-ecd by hTSHR-Ab, serial dilutions of the standard Graves' serum and mAb A10 were reacted with folded and reduced (unfolded) mTSHR-ecd. The folding state of the mTSHR-ecd had little influence on the binding of mAb A10, as expected from its highly restricted epitope located in a region probably not affected by folding (Fig.  7B) . In contrast, reduction of the folded ectodomain markedly diminished, but did not abolish, the binding of standard Graves' TSHR-Ab (Fig. 7C) . Approximately 75% of the activity was lost when expressed in relation to mAb A10 binding, indicating that the folding state of the mT-SHR-ecd was an important determinant of the degree of hTSHR-Ab binding. 
Discussion
The TSHR is the primary antigen of the human autoimmune thyroid disease known as Graves' disease (30) . This disorder is a uniquely human abnormality associated with T cells and autoantibodies to the TSHR. In particular, the TSHR-Ab may act as TSH agonists and induce the thyroid overactivity characteristic of the disease (2). Alternatively, some TSHR-Ab may act as TSH antagonists and reduce thyroid function (31) . There are currently no animal models of Graves' disease. We believe, therefore, that the characterization of the mouse thyroidal TSHR antigen may be important because the mouse is the most appropriate animal for the development of a Graves' disease model considering the profusion of immunological reagents available for such murine studies. In support of this concept is the use of the mouse as a bioassay for hTSHR-Ab, which are known to cross-react with the mTSHR (3). However, only 15% of human stimulatory TSHR-Ab bind and stimulate the mouse receptor; the remaining autoantibodies bind and act as neutral autoantibodies or are TSH antagonists (4) . Hence, significant structural/immunological differences must be present between the mouse and human TSHRs. This was supported by the sequence data. Although there were only six primarily conservative amino acid substitutions in our mTSHR-ecd sequence compared with that published for the BALB/c mouse (7), most likely due to mouse strain differences, comparison of the mTSHR-ecd sequence with the human sequence gave different information. Although there was an overall 85% similarity, it was apparent that a number of significant differences were present, particularly in the N-and C-terminal regions. These structural differences between hTSHR-ecd and mTSHR-ecd, which lead to different computed indexes of average hydrophilicity profiles (15) , are likely to form the basis of the dissimilarities in structure-function relationships shown by hTSHR-Abs and require more detailed evaluation.
Using a baculovirus-insect cell system, we synthesized and purified the murine TSHR-ecd and characterized the product as a test antigen. Compared to our previous data (18) and those of other workers (32, 33) , we obtained a much higher degree of purity as well as quantity of soluble recombinant TSHR-ecd. Affinity-purified antigen was present as two major species [glycosylated (66 kDa) and unglycosylated (52 kDa)] as well as minor, partially glycosylated forms. The purified mTSHR-ecd inhibited binding of radiolabeled TSH to CHO cells expressing functional hTSHRs and provided indirect evidence of TSH binding to the recombinant product. The fact that the refolded mTSHR-ecd inhibited [ 125 I]TSH binding with a similar affinity as the natively folded (cytosolic) mTSHR-ecd confirmed the correct refolding of this preparation. However, the level of inhibition was less than that attained using solubilized porcine TSHR. This lower reactivity could be partly explained by the lower af- FIG. 7 . Binding of hTSHR-Ab to refolded mTSHR-ecd. A, Recognition of refolded mTSHR-ecd by the MRC standard Graves' TSHR Ab. mAb A9 recognized both murine and human TSHR-ecd. Similarly, the MRC standard Graves' TSHR-Ab had a high reactivity for both murine and human TSHR-ecd, but did not react with wild-type baculovirus-infected insect cell lysate (control) or BSA. B, Binding of mAb A10 to the mTSHR-ecd is folding independent. The mAb A10 recognized both refolded and unfolded mTSHR-ecd preparations with similar reactivities. C, Binding of hTSHR-Ab to the mTSHR-ecd is folding dependent. Two-fold dilutions of the MRC Graves' standard serum were reacted with refolded and unfolded mTSHR-ecd, and the results are expressed as a percentage of mAb A10 recognition. As opposed to mAb A10, the MRC Graves' standard serum clearly preferred the folded, rather than the unfolded, state of the mTSHR-ecd.
FIG. 8. Binding of Graves' sera to the purified mTSHR-ecd. As a positive control, mAb A9 (1:50,000 dilution) recognized the mTSHRecd. Although none of the 6 normal sera (1:50 dilution) bound to the mTSHR-ecd, 4 of the 14 Graves' sera tested were highly reactive. Note the MRC standard serum (no. 8) and Graves' sera 16, 17, 19, and 20 . None of the normal or Graves' sera reacted with control antigens (BSA).
finity of TSH for the mTSHR (our unpublished observations). Indeed, native mTSHR has been shown to exhibit 1 order of magnitude lower affinity for TSH compared to the hTSHR (5) .
There are at least two alternative explanations for the lower affinity of the mTSHR-ecd for TSH; the absence of the transmembrane region and differences in the glycosylation status of the recombinant product. Although it is generally agreed that the large ectodomain of glycoprotein receptors is primarily involved in ligand binding, and the transmembrane domain is involved in signal transduction, the issue of whether these domains must interact for high affinity binding remains open. Recent studies have shown that the hyt/hyt mutation in the mTSHR (Pro 556 Leu in the fourth transmembrane region), abolished TSH binding and receptor function (34) . Similarly, mutation of Asp 383 to Asn in the second transmembrane region of the LH receptor (35) , significantly lowered the affinity of lutropin ligand for its receptor. These studies suggest that the transmembrane region may be important for direct high affinity ligand binding or may indirectly stabilize the ligand-ectodomain binding complex. However, studies comparing binding of TSH by the ␣-subunit of the hTSHR (lacking the transmembrane region) and solubilized full-length hTSHR of transfected cells (36) could not find significant ligand binding affinity differences, although these binding affinities were inexplicably low (10 Ϫ5 m). Similarly, studies comparing binding of LH to insect cell-expressed full-length and truncated LH receptors (37) could not detect significant differences, although both were 1 order of magnitude less than the natural ovarian LH receptor. Further studies are clearly necessary to clarify the role of the transmembrane region in ligand binding. As far as the glycosylation status of the mTSHR-ecd was concerned, most of the insect cell-expressed murine ectodomain was glycosylated in a high mannose state. It has previously been demonstrated that TSH was able to bind, albeit with a lower affinity, to insect cell-expressed, nonglycosylated, refolded hTSHR-ecd (26) . In contrast, Zhang et al. (37) have shown that tunicamycin-treated insect cells expressing a carbohydratefree LH receptor lacked ligand-binding activity, as opposed to insect cell LH receptor glycosylated in a high mannose state. Hence, the LH and TSH receptors may differ in their requirements for ligand binding. Our data showed that the high mannose glycosylation of the mTSHR-ecd did not hinder TSH binding. Indeed, differential enzymatic cleavage of insect cell-expressed LH receptor has shown that only the proximal N-acetylglucosamine residue, common to both high mannose and complex carbohydrate side-chains, is necessary for acquisition of a correctly folded receptor that binds LH with high affinity (37) . Therefore, the folding status seems to be more important than glycosylation in ligand binding.
We thought that for physiological characterization, a soluble, correctly folded recombinant mTSHR-ecd product was necessary. Obtaining a soluble form of recombinant TSHRecd has been problematic. Harsh preparative techniques were originally used to render prokaryotic products soluble (20) , although new procedures for hydrophilic products have been recently described (38) . With eukaryotic insect cell systems, however, either no soluble product was found or only very small quantities of soluble receptor were identified after extensive purification (32) . In the present studies, 100-g amounts of soluble cytosolic mTSHR-ecd were obtained, enough to allow a quantitative, direct comparison to the initially insoluble forms that were rendered soluble by in vitro refolding. Both the molecular sizes and degrees of glycosylation appeared identical, and both products competed with radiolabeled TSH with equal avidity. The unfolding of the mTSHR-ecd resulted in marked diminution of TSH binding to the recombinant product. Hence, the final folding status of the product was more important than the initial solubility status. The purified mTSHR-ecd also bound some, but not all (30%), of the human TSHR autoantibodies present in the sera of selected patients with hyperthyroid Graves' disease. In contrast with the monoclonal antibodies, human autoantibodies from patients with Graves' disease had a higher affinity for the folded state, indicating the presence of antibodies to important conformationally dependent epitopes. Similar results were obtained from structure-activity studies of thyroid peroxidase autoantigen and thyroid peroxidase antibodies (25) . Unfolding the mTSHR-ecd did not totally abolish autoantibody recognition, as 25% of the binding remained. Hence, linear epitopes are also viable interaction sites for human TSHR-Abs, in agreement with their significant, but low, affinity recognition of prokaryotic antigen (18, 20) .
In conclusion, we have succeeded in generating large quantities of biologically active mTSHR-ecd. However, compared to the natural TSHR, the binding of TSH was of lower affinity and was recognized by only 30% of hTSHRAbs from patients with Graves' disease. The fact that only a minority of TSHR autoantibodies bound both natural TSHR and recombinant mTSHR-ecd suggested that structural differences existed between them. Such differences may have been secondary to the lack of the transmembrane region in the recombinant product, variation in the glycosylation status, or differences in the protein structures of the ectodomains. These structural dissimilarities are likely to generate fine changes in nonlinear epitopes, which may only be mapped knowing the crystallographic structure of the molecule.
